Investor Presentaiton
Solid Q3 in Ostomy Care with broad-based growth of 8%. China grew
double-digit due to a lower baseline and normalized hospital activity
13
19
10
Ostomy Care performance
6
8
8
5
4
5
2,160
2,253
2,274
2,204
2,246
III
•
Q3 2022/23 highlights
All regions contributed to growth in the quarter
Strong quarter in Emerging markets, led by China
China posted double-digit growth, as expected, and benefited from a
lower baseline last year. Hospital access and procedural volumes fully
normalized during the quarter, resulting in a return of inflow of new
patients back to pre-covid levels
Continued good momentum in Europe, especially the UK, as well as
the US
From a product perspective, the SenSuraⓇ Mio portfolio, and in particular
SenSuraⓇ Mio Convex, was the main growth contributor, followed by the
BravaⓇ range of supporting products
9
6
Q3 21/22 Q4 21/22
Q1 22/23
Q2 22/23
Q3 22/23
Revenues (DKKm)
Organic growth (%)
Reported growth (%)
ColoplastView entire presentation